/
Oncology
Malignant Solid Tumor
21
Pipeline Programs↗
7
Active Trials↗
16
Companies Involved↗
Malignant Solid Tumor is an emerging landscape with 21 programs across 16 companies. The most active players are Genmab, Ono Pharmaceutical Co. Ltd.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 14
Phase 29
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
89%
Small molecule
17 of 19 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 95% of 21 pipeline programs.
Analysis
Trial Status
11
clinical trials
Recruiting4 · 36%
Completed2 · 18%
Active, not recruiting2 · 18%
Terminated1 · 9%
Enrolling by invitation1 · 9%
Withdrawn1 · 9%
Clinical Trials
Trial Activity
11 trials
A Single-Center, Prospective, Open-Label, Two-Cohort Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Diagnostic Performance of [68Ga]Ga-ELI411 PET Imaging in Chinese Adult Patients With Solid Tumors
Enrolling by invitation·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT07741006·18 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)